DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy
DBV Technologies S.A. - American Depositary Shares (DBVT)
US:NASDAQ Investor Relations:
dbv-technologies.com/en/investor-relations
Company Research
Source: GlobeNewswire
Montrouge, France, January 8, 2020 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment Low discontinuations due to adverse events observed Study represents the largest long-term peanut allergy immunotherapy trial to date, with high compliance enabling extended study participation DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial (PEOPLE) evaluating the long-term efficacy and safety of investigational Viaskin® Peanut in peanut-allergic children ages 4 to 11 years. The results demonstrate long-term clinical benefit as shown by an increase in eliciting dose (ED), which
Show less
Read more
Impact Snapshot
Event Time:
DBVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DBVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DBVT alerts
High impacting DBV Technologies S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
DBVT
News
- DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-OldGlobeNewswire
- DBV Technologies S.A. (NASDAQ: DBVT) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $10.00 price target on the stock.MarketBeat
- DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
DBVT
Earnings
- 11/6/24 - Beat
DBVT
Sec Filings
- 12/18/24 - Form 8-K
- 12/16/24 - Form 8-K
- 12/11/24 - Form 8-K
- DBVT's page on the SEC website